Scientific Poster Session IV - Original Research

Abstract

Research Question or Hypothesis: The goal of this study was to determine if clevidipine infusions can safely and effectively reach blood pressure targets and maintain blood pressure control without undesirable variability in patients with neurologic emergencies

Study Design: This was a prospective, single arm, observational study.

Methods: We enrolled a convenience sample of adult patients hospitalized for AIS, ICH, SAH or posterior reversible encephalopathy syndrome (PRES) who required clevidipine for blood pressure control within 24 hours of symptom onset between 10/2021-8/2022. Patients were included in the analysis if they received clevidipine for a minimum of 6 hours within the first 24 hours of intensive care unit admission. The primary efficacy outcome was systolic BPV during the first hour. The primary safety outcomes were acute neurological decline and acute kidney injury (AKI) defined by the KDIGO criteria. Secondary outcomes were BPV within 24 hours.

Results: Thirty patients were enrolled with a median age of 64 (58,77) and most were white (83.3%) and female (57%). The most common primary diagnosis was ICH (63%). The mean (SD) systolic BPV in the first hour as measured by standard deviation was 17.2 (9.3), as measured by average real variability was 17.2 (10.5), and as measured by coefficient of variation was 10.9 (5.6). At 24 hours the mean systolic BPV by standard deviation was 16.4 (5.6). Six patients (20%) experienced AKI.

Conclusion: Clevidipine may be an effective and safe option to treat acute hypertension in acute cerebrovascular diseases. Comparative studies evaluating BPV are needed.

Presenting Author

Authors